All In Biotech

Drug Trial Radar · NCT06692764

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

A Phase II Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants With Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-Density Lipoprotein Cholesterol

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Oct 30, 2024

Primary completion

Apr 18, 2025

Study completion May 2, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Fortrea
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants with ASCVD or risk equivalents and LDL-C ≥ 70 mg/dL, on stable medication.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • PlaceboDrug

    0 mg (Placebo). Participants will receive three bottles, each containing 35 tablets with placebo tablets. Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose.

  • AZD0780Drug

    Dose 1 Participants will receive three bottles, each containing 35 tablets: * 1 bottle of dose a AZD0780 tablets * 1 bottle of dose b AZD0780 tablets * 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the effect of treatment with AZD0780 dose 1 versus placebo on ambulatory 24-hour average SBP at Week 4Time frame: Week 4

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Inglewood, California

  • Research Site

    Northridge, California

  • Research Site

    Pomona, California

  • Research Site

    Boca Raton, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Tamarac, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Potomac, Maryland

  • Research Site

    New Bedford, Massachusetts

  • Research Site

    New Windsor, New York

  • Research Site

    Beavercreek, Ohio

  • Research Site

    Horsham, Pennsylvania

  • Research Site

    Spartanburg, South Carolina

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    El Paso, Texas

  • Research Site

    Hurst, Texas

  • Research Site

    Mesquite, Texas

  • Research Site

    Paris, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.